biostudies-literaturevan Gils VUK Dementia Research InstituteCure Alzheimer's FundAlzheimer's Drug Discovery FoundationInnovative Medicines InitiativesHealth HollandSwedish Research CouncilHjärnfonden, SwedenAutonomous Government of CataloniaStiftelsen för Gamla TjänarinnorMarie Curie International Training NetworkAlzheimer&apos;s AssociationOlav Thon FoundationEU/EFPIA Innovative Medicines Initiative Joint UndertakingNational MS SocietyUnion Joint Programme - Neurodegenerative Disease ResearchFamiljen Rönströms StiftelseTopsector Life Sciences &amp; HealthCare Research University College London Hospitals Biomedical Research CentreBluefield ProjectDutch Research Council (NWO)Cure Alzheimer&apos;s Fundthe Erling-Persson Family FoundationEuropean Union's Horizon Europe research and innovation programmeAlzheimer's AssociationDutch National Dementia StrategyVetenskapsrådetZonMwNational Institute for HealthMarie Skłodowska-CurieThe Selfridges Group FoundationEuropean Community's Horizon H2020/2014 - 2020Swedish State Support for Clinical Researche70804https://www.ebi.ac.uk/biostudies/studies/S-EPMC12573102biostudies-literatureUnknown21(10)<h4>Introduction</h4>It remains unclear whether diabetes mellitus (DM) is associated with Alzheimer's disease (AD) pathology and associated vascular burden.<h4>Methods</h4>We included cognitively normal (CN), mild cognitive impairment (MCI), and dementia individuals. We assessed associations between DM and AD biomarkers (amyloid beta [Aβ], phosphorylated tau-181 [p-tau181], total tau [t-tau], and medial temporal atrophy [MTA]) and vascular burden (white matter hyperintensities, microbleeds) by logistic regression. Secondary analyses assessed associations between DM and profiles of Aβ combined with p-tau181/t-tau/MTA/white matter hyperintensity/microbleeds.<h4>Results</h4>We included 5550 participants (65.8+-8.7 years, 8.7% DM). DM was associated with lower odds of abnormal AD biomarkers: AAlzheimer's & dementia : the journal of the Alzheimer's AssociationThe association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts.PMC12573102#2023‐00356860197101034344#2022‐0101810510032120003831434115736#ADSF-21-831381-CJPND2021-00694#10510032120003101053962#201809-2016862#ADSF-24-1284328-C#2019-02397SG21‐818099‐EPAD#2022-01018#2019‐02397#2023-00356UKDRI-1003#ADSF-21-831377-C73305095007#ADSF-21-831376-C#LSHM20106#FO2022-0270#73305095007847879SG21-818099-EPADvan der Flier WMFrolich LWallin AMoonen JSalas‐Salvado JStreffer JVos SJBDalsgaard SJansen WJEngelborghs SBralten JRamakers IHGBLovestone SDamian DFranke BZetterberg HFanelli GLegdeur NRouaud Ovan Harten AHall APopp JPoelmans GJimenez-Murcia SFreund-Levi Yvan Gils VBullo MVandenberghe RTsolaki MVeverova KFernandez‐Aranda Fden Braber ALleo AMartinez-Lage PVisser PJHort JLaakso MTeunissen CEfalseThe association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts.<h4>Introduction</h4>It remains unclear whether diabetes mellitus (DM) is associated with Alzheimer's disease (AD) pathology and associated vascular burden.<h4>Methods</h4>We included cognitively normal (CN), mild cognitive impairment (MCI), and dementia individuals. We assessed associations between DM and AD biomarkers (amyloid beta [Aβ], phosphorylated tau-181 [p-tau181], total tau [t-tau], and medial temporal atrophy [MTA]) and vascular burden (white matter hyperintensities, microbleeds) by logistic regression. Secondary analyses assessed associations between DM and profiles of Aβ combined with p-tau181/t-tau/MTA/white matter hyperintensity/microbleeds.<h4>Results</h4>We included 5550 participants (65.8+-8.7 years, 8.7% DM). DM was associated with lower odds of abnormal AD biomarkers: A2025-01-01T00:00:00Z2025 Oct2026-06-06T14:42:07.251Z2026-06-01T03:06:39.628ZS-EPMC125731024116507210.1002/alz.70804